Method for treating a GD2 positive cancer
Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.
1. A method of treating neuroblastoma in a human patient comprising administering ch14.18 antibody in at least one treatment cycle, the at least one treatment cycle comprising at least one treatment period and optionally one or more days of no administration of the ch14.18 antibody to the patient between repeated treatment periods, wherein the treatment period is one or more consecutive days when the ch14.18 antibody is administered to the patient, the ch14.18 antibody being administered in a dose of or between 10 to 20 mg/m 2 /day by intravenous infusion over 10 to 24 hours per day to the patient without administering IL-2 within the same one or more treatment cycles, wherein the ch14.18 antibody comprises a heavy chain and a light chain, the heavy chain having an amino acid sequence comprising SEQ ID NO:4 and the light chain having an amino acid sequence comprising SEQ ID NO:3, and wherein a neuroblastoma is treated in the patient.
2. The method of claim 1 , further comprising treating the patient one or more times with a retinoid preceding, accompanying, and/or following administering of the ch14.18 antibody.
3. The method of claim 1 , wherein the ch14.18 antibody is administered to the patient as a continuous intravenous infusion over 24 hours per day for one or more days.
4. The method of claim 1 , wherein the ch14.18 antibody is administered to the patient for two or more treatment cycles.
5. The method of claim 1 , wherein the patient is not treated with GM-CSF within the same one or more treatment cycles.
6. The method of claim 1 , wherein the patient is not treated with a cytokine within the same one or more treatment cycles.
7. The method of claim 1 , wherein the patient is not treated with IL-2, and/or GM-CSF, and/or a cytokine within the same one or more treatment cycles and/or within an overall treatment time that comprises one or more treatment cycles and optionally one or more days of no administration of the ch14.18 antibody to the patient between repeated treatment cycles.
8. The method of claim 1 , wherein the neuroblastoma is high risk neuroblastoma, neuroblastoma stage 4, minimal residual neuroblastoma disease, relapsed neuroblastoma, and/or refractory neuroblastoma.
9. The method of claim 1 , wherein the ch14.18 antibody administered to the patient is a CHO cell or SP2/0 cell produced antibody.
10. The method of claim 1 , wherein the ch14.18 antibody is administered in a daily dose of 10 or 20 mg/m 2 .
11. The method of claim 1 , wherein the ch14.18 antibody is administered for 4, 10, 14, 15, or 21 consecutive days.
12. The method of claim 1 , wherein the ch14.18 antibody is administered in a preparation further comprising sucrose, polysorbate 20, histidine, and hydrochloric acid.
13. The method of claim 12 , wherein the preparation comprises 4.5 mg/mL ch14.18 antibody, 50 mg/mL sucrose, 0.1 mg/mL polysorbate 20, and 3.1 mg/mL histidine.
14. The method of claim 1 , wherein the ch14.18 antibody is administered in a dose of 10 mg/m 2 /day for 10 consecutive days for 1, 2, 3, 4, 5, 6 or more treatment cycles.
15. The method of claim 1 , wherein the ch14.18 antibody administered to the patient is a CHO cell produced ch14.18 antibody.
16. The method of claim 1 , wherein the ch14.18 antibody administered to the patient is a SP2/0 cell produced ch14.18 antibody.
17. The method of claim 1 , wherein the administration of the ch14.18 antibody is accompanied by the administration of a reduced dose of morphine and/or one or more other analgesic.
18. The method of claim 1 , wherein the ch14.18 antibody is administered in a dose of 60, 70, 75, 80, or 100 mg/m 2 /treatment cycle.
19. The method of claim 1 , wherein the patient is not treated with IL-2 within an overall treatment time that comprises one or more treatment cycles and optionally one or more days of no administration of the ch14.18 antibody to the patient between repeated treatment cycles.
20. The method of claim 1 , wherein the ch14.18 antibody is a humanized ch14.18 antibody.
21. The method of claim 1 , wherein the patient is not treated with IL-2, GM-CSF, or a cytokine within an overall treatment time that comprises one or more treatment cycles and optionally one or more days of no administration of the ch14.18 antibody to the patient between repeated treatment cycles.